Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Jul;136(1):132-5.
doi: 10.1016/s0002-8703(98)70193-0.

The evolving costs of intracoronary stents

Affiliations
Comparative Study

The evolving costs of intracoronary stents

P T Vaitkus et al. Am Heart J. 1998 Jul.

Abstract

Background: As stenting practice has evolved to include greater numbers of stents and adjunctive balloon catheters per case, concern has focused on the increasing costs of equipment for the delivery of stents.

Methods and results: To evaluate temporal changes in costs of intracoronary stenting, we examined total costs, catheterization laboratory equipment costs, equipment utilization, and nonlaboratory hospital costs for stent cases for two time periods: Period I (n = 46; 3 months in 1995 involving routine warfarin anticoagulation) and Period II (n = 129; 4 months during which warfarin was being abandoned). Overall costs declined from Period I ($11,293+/-$7672) to Period II ($9819+/-$3636) (p = 0.074). Catheterization laboratory equipment expenditures rose (Period I, $3823+/-$1394 vs Period II, $4278+/-$1533), whereas noncatheterization laboratory hospital costs declined significantly (Period I, $7281+/-$7179 vs Period II, $5560+/-$3420). The difference in costs was most notable when taking into account the deletion of warfarin anticoagulation. Costs declined by $2428 for patients in Period II in whom warfarin was not prescribed (p < 0.05 vs patients in Period I).

Conclusions: We conclude that despite the increasing costs for equipment of stent cases, our overall costs of providing stents declined as warfarin anticoagulation was abandoned.

PubMed Disclaimer

Comment in

  • Squeezing the "value" from cost data.
    Kong DF, Peterson ED. Kong DF, et al. Am Heart J. 1998 Jul;136(1):1-3. doi: 10.1016/s0002-8703(98)70172-3. Am Heart J. 1998. PMID: 9665209 Review. No abstract available.

Publication types

MeSH terms

LinkOut - more resources